These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 19653263

  • 21. Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
    Duong C, Greenawalt DM, Kowalczyk A, Ciavarella ML, Raskutti G, Murray WK, Phillips WA, Thomas RJ.
    Ann Surg Oncol; 2007 Dec; 14(12):3602-9. PubMed ID: 17896157
    [Abstract] [Full Text] [Related]

  • 22. High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus.
    Kajiwara T, Nishina T, Hyodo I, Moriwaki T, Endo S, Nasu J, Hori S, Matsuura B, Hiasa Y, Onji M.
    Oncology; 2009 Dec; 76(5):342-9. PubMed ID: 19307741
    [Abstract] [Full Text] [Related]

  • 23. Quantitative analysis of survivin in colorectal adenocarcinoma: increased expression and correlation with telomerase activity.
    Lam AK, Saleh S, Smith RA, Ho YH.
    Hum Pathol; 2008 Aug; 39(8):1229-33. PubMed ID: 18547619
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
    Miyata H, Yoshioka A, Yamasaki M, Nushijima Y, Takiguchi S, Fujiwara Y, Nishida T, Mano M, Mori M, Doki Y.
    Cancer; 2009 Jul 15; 115(14):3324-34. PubMed ID: 19452547
    [Abstract] [Full Text] [Related]

  • 26. TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer.
    Warnecke-Eberz U, Metzger R, Bollschweiler E, Baldus SE, Mueller RP, Dienes HP, Hoelscher AH, Schneider PM.
    Pharmacogenomics; 2010 Jan 15; 11(1):55-64. PubMed ID: 20017672
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
    Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK.
    J Urol; 2006 Jun 15; 175(6):2312-6. PubMed ID: 16697865
    [Abstract] [Full Text] [Related]

  • 30. Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer.
    Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Mori M, Doki Y.
    J Surg Oncol; 2009 Nov 01; 100(6):442-6. PubMed ID: 19653262
    [Abstract] [Full Text] [Related]

  • 31. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma.
    Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Tanaka H, Miki K, Kobayashi K, Morita K.
    Surgery; 2008 Nov 01; 144(5):729-35. PubMed ID: 19081014
    [Abstract] [Full Text] [Related]

  • 32. Prognostic impact of blood biomarkers TS and DPD in neoadjuvant-treated esophageal cancer patients.
    Grimminger PP, Maus MK, Bergenthal J, Wandhöfer C, Fetzner UK, Herbold T, Bollschweiler E, Hölscher AH, Brabender J.
    Anticancer Res; 2015 Mar 01; 35(3):1297-302. PubMed ID: 25750278
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
    Khan Z, Tiwari RP, Mulherkar R, Sah NK, Prasad GB, Shrivastava BR, Bisen PS.
    Head Neck; 2009 Aug 01; 31(8):1039-48. PubMed ID: 19340865
    [Abstract] [Full Text] [Related]

  • 35. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
    Ichiki Y, Hanagiri T, Takenoyama M, Baba T, Fukuyama T, Nagata Y, Mizukami M, So T, Sugaya M, Yasuda M, So T, Sugio K, Yasumoto K.
    Lung Cancer; 2005 May 01; 48(2):281-9. PubMed ID: 15829330
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Survivin products in pituitary tumors.
    Jankowska A, Wasko R, Waligorska-Stachura J, Andrusiewicz M, Jaskula M, Liebert W, Sowinski J.
    Neuro Endocrinol Lett; 2008 Dec 01; 29(6):1033-7. PubMed ID: 19112393
    [Abstract] [Full Text] [Related]

  • 38. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
    Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N.
    Urol J; 2009 Dec 01; 6(2):101-8. PubMed ID: 19472128
    [Abstract] [Full Text] [Related]

  • 39. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas.
    Kitsukawa S, Aoyagi T, Noda K, Ito T, Yamamoto Y, Hosoda S, Otsuru N, Matsumoto T.
    Hinyokika Kiyo; 2008 Feb 01; 54(2):101-6. PubMed ID: 18323166
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.